[[2,7-Bis(2-morpholin-4-ylethoxy)fluoren-9-ylidene]amino]thiourea

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: [[2,7-Bis(2-morpholin-4-ylethoxy)fluoren-9-ylidene]amino]thiourea
• 化学式: C₂₆H₃₃N₅O₄S
• mdl: MFCD00985324
• 分子量: 511.6
• InChiKey: VWTYTVOZWMPXBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  126
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans
  申请人：Regen BioPharma, Inc.

  公开号：US20180214413A1

  公开（公告）日：2018-08-02

  The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to humans.

  目前的技术是针对核受体活性调节剂，具体是针对NR2F6活性的调节和利用NR2F6化合物的调节，以及通过将本文描述的化合物用于人体来进行免疫调节和调节癌症干细胞活性。
• Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand
  申请人：Regen BioPharma, Inc

  公开号：US10088485B2

  公开（公告）日：2018-10-02

  The current invention discloses compositions of matter, protocols and methods of screening test compounds to identifying agonists and antagonists of the orphan nuclear receptor NR2F6 by measuring the ability of a test compound to occupy the active site of NR2F6, in the presence of a reference compound.

  本发明公开了筛选试验化合物的物质组合物、方案和方法，通过测量试验化合物在参比化合物存在的情况下占据 NR2F6 活性位点的能力，确定孤儿核受体 NR2F6 的激动剂和拮抗剂。
• Small molecule agonists and antagonists of NR2F6 activity in animals
  申请人：Zander Therapeutics, Inc.

  公开号：US10472351B2

  公开（公告）日：2019-11-12

  The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to animals.

  本技术针对核受体活性调节剂，特别是针对 NR2F6 活性调节和 NR2F6 利用化合物，以及通过对动物施用本文所述化合物进行免疫调节和癌症干细胞活性调节。
• Small molecule modulators of NR2F6 activity
  申请人：Regen Biopharma, Inc.

  公开号：US11241427B2

  公开（公告）日：2022-02-08

  Disclosed are compounds useful for alteration of NR2F6 activity. In some embodiments of the invention compounds disclosed are utilized for stimulation of NR2F6 activity, alone, or in combination with PKC activation. In other embodiments, the invention teaches use of compounds for inhibition of NR2F6 activation. Stimulation of NR2F6 within the context of the invention is useful, intra alia, for induction of immune inhibition, or stimulation of cellular proliferation without significant induction of differentiation. Inhibition of NR2F6 is desired in situations where the practitioner of the invention seeks to augment immune response, or induce cellular differentiation. In another embodiment, inhibition of NR2F6 expression is desired in situations where inhibition of cancer or cancer stem cells is needed.

  本发明公开了可用于改变 NR2F6 活性的化合物。在本发明的某些实施方案中，所公开的化合物可单独或与 PKC 激活相结合用于刺激 NR2F6 活性。在其他实施方案中，本发明教导使用化合物来抑制 NR2F6 的活化。在本发明的背景下，刺激 NR2F6 特别适用于诱导免疫抑制或刺激细胞增殖而不显著诱导分化。在本发明实施者试图增强免疫反应或诱导细胞分化的情况下，需要抑制 NR2F6。在另一个实施方案中，在需要抑制癌症或癌症干细胞的情况下，需要抑制 NR2F6 的表达。
• Small molecule agonists and antagonists of NR2F6 activity
  申请人：ZANDER THERAPEUTICS, INC.

  公开号：US11377442B2

  公开（公告）日：2022-07-05

  The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein.

  本技术针对核受体活性调节剂，特别是针对 NR2F6 活性调节和 NR2F6 利用化合物，以及通过服用本文所述化合物进行免疫调节和癌症干细胞活性调节。